Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to $65.6 million.

  • Burning Rock Biotech's Cash & Equivalents fell 755.92% to $65.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.6 million, marking a year-over-year decrease of 755.92%. This contributed to the annual value of $71.5 million for FY2024, which is 1744.35% down from last year.
  • Burning Rock Biotech's Cash & Equivalents amounted to $65.6 million in Q3 2025, which was down 755.92% from $63.2 million recorded in Q2 2025.
  • Burning Rock Biotech's 5-year Cash & Equivalents high stood at $318.3 million for Q1 2021, and its period low was $63.2 million during Q2 2025.
  • Moreover, its 5-year median value for Cash & Equivalents was $101.0 million (2023), whereas its average is $135.8 million.
  • As far as peak fluctuations go, Burning Rock Biotech's Cash & Equivalents crashed by 4455.59% in 2022, and later tumbled by 755.92% in 2025.
  • Quarter analysis of 5 years shows Burning Rock Biotech's Cash & Equivalents stood at $185.8 million in 2021, then fell by 29.36% to $131.3 million in 2022, then plummeted by 34.01% to $86.6 million in 2023, then decreased by 17.79% to $71.2 million in 2024, then decreased by 7.9% to $65.6 million in 2025.
  • Its Cash & Equivalents was $65.6 million in Q3 2025, compared to $63.2 million in Q2 2025 and $68.5 million in Q1 2025.